| GTO ID | GTC3279 |
| Trial ID | NCT05654077 |
| Disease | Nasopharyngeal Disease |
| Altered gene | EBV |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | EBV CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | EBV CAR-T Cells for Nasopharyngeal Carcinoma |
| Year | 2022 |
| Country | China |
| Company sponsor | The Affiliated Hospital of Xuzhou Medical University |
| Other ID(s) | BR-EB-10 |
| Cohort 1 | |||||||||||
|
|||||||||||